# Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

> **NCT03137173** · PHASE3 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 679 (actual)

## Conditions studied

- Acute Bacterial Skin and Skin Structure Infections

## Interventions

- **DRUG:** ceftobiprole medocaril
- **DRUG:** vancomycin+aztreonam

## Key facts

- **NCT ID:** NCT03137173
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-19
- **Primary completion:** 2019-04-22
- **Final completion:** 2019-04-22
- **Target enrollment:** 679 (ACTUAL)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137173, "Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03137173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*